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Background
C-reactive protein (CRP) is synthesized in the
liver in response to interleukin and other cytokine
polypeptides which are released from sites of
inflammation. Infections, burns, tissue necrosis,
wounds, surgery, stress or psychiatric conditions,
and atherosclerosis can precipitate the release of
CRP.
CRP amounts are thought to be
proportional to the extent of tissue damage.1,2
High-sensitivity CRP tests (hs-CRP) are
preferred over classic CRP testing due to their
ability to detect CRP levels below 1 mg/L.2
The possible beneficial effects of statins have
been described for several diseases, including
Alzheimer’s
disease,
multiple
sclerosis,
nonischemic cardiomyopathy, prevention of bone
fractures, infection, and some types of cancer.
The generalized anti-inflammatory action of the
statins has been proposed as a possible
explanation.3,4
In the Pravastatin or Atorvastatin Evaluation
and Infection Therapy – Thrombolysis in
Myocardial Infarction 22 (PROVE IT – TIMI 22)
trial comparing an aggressive LDL-lowering
atorvastatin 80 mg regimen with a moderate LDLlowering pravastatin 40 mg regimen, improved
cardiovascular outcomes for aggressive statin
therapy were demonstrated.5 The Reversing
Atherosclerosis with Aggressive Lipid Lowering
(REVERSAL) trial, using the same statin
regimen, identified a reduced rate of progression
of atherosclerosis with the intensive lipidlowering atorvastatin regimen.6 Both studies
revealed significant reductions in CRP levels with
aggressive statin therapy.3,7

Citation
Ridker PM, Cannon CP, Morrow D, et al. Creactive protein levels and outcomes after statin
therapy. N Engl J Med 2005;352:20-8.

Methods
This study by Ridker et al was a substudy of
PROVE IT – TIMI 22. It consisted of 3,745
participants representing 90% of the original study
cohort. PROVE IT – TIMI 22 was a randomized
trial between November 2000 and February 2004
which compared the effect of intensive statin
therapy (atorvastatin 80 mg daily) with moderate
statin therapy (pravastatin 40 mg daily) and of
gatifloxacin and placebo on the risk of recurrent
coronary events after acute coronary syndromes.5
Members of the substudy population were alive
and free of recurrent events 30 days after the
study’s end.
Each participant had plasma
measurements of both LDL cholesterol and hsCRP at baseline randomization, 30 days, four
months, and at the end of the study. The achieved
levels of these two measures was defined as those
obtained at the 30-day follow-up visit. The study
population was divided into quartiles based on the
levels of achieved LDL cholesterol and achieved
CRP. The population was further divided on the
basis of the approximate median achieved LDL
cholesterol level (70 mg/dL) and the approximate
median achieved CRP level (2 mg/L). These
values served as target levels for the study.
Researchers evaluated whether the rates of events
differed between patients with values above the
median and those below the median.

Results
The levels of both LDL cholesterol and CRP
were reduced by the statin therapy at the end of 30
days. Intensive atorvastatin therapy reduced LDL
cholesterol levels to below 70 mg/dL and CRP
levels to below 2 mg/L more effectively than
moderate pravastatin therapy. There was little
evidence that either agent led to better clinical
outcomes once target LDL cholesterol and CRP
levels were achieved. Achieving both of these
target levels was of greater importance for eventMore. . .
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free survival than was the type of statin therapy.
The correlation (r) between achieved LDL
cholesterol levels and achieved CRP levels was
small (r = 0.16, P = 0.001). Less than 3% of the
variance in achieved CRP levels was explained by
the variance in achieved LDL cholesterol.
Recurrent myocardial infarctions or deaths in the
study population were expressed as age-adjusted
events per 100 patient years. These results are
expressed below.
LDL/CRP
Event
P Value**
Level*
Rate
LDL > 70
4.0
0.008
LDL < 70
2.7
CRP > 2
3.9
0.006
CRP < 2
2.8
LDL > 70 &
4.6
<0.001
CRP > 2
LDL < 70 &
3.1
CRP > 2
LDL > 70 &
3.2
CRP< 2
LDL < 70 &
2.4
CRP< 2
CRP > 1
3.8
<0.001
CRP < 1
2.1
LDL > 70 &
4.5
<0.001
CRP > 1
LDL < 70 &
3.1
CRP > 1
LDL > 70 &
2.3
CRP< 1
LDL < 70 &
1.9
CRP< 1
*LDL units = mg/dL, CPR units = mg/L
**P values for comparison between two or
among four groups

Author Conclusions
Despite resultant levels of LDL cholesterol,
patients who had low CRP levels after statin
therapy had better clinical coronary outcomes than
those with higher CRP levels. Monitoring CRP
and LDL cholesterol should be used in lowering
cardiovascular risks with statin therapy.

Commentary
This substudy of PROVE IT – TIMI 22 offers
the first evidence suggesting that CRP is an
independent factor useful in monitoring and

adjusting statin therapy. Event rates were similar
for LDL < 70 mg/dL and CRP > 2 mg/L
compared with LDL > 70 mg/dL and CRP < 2
mg/L at 3.1 vs. 3.2 events per 100 patient-years,
respectively. Furthermore, event rates for LDL <
70 mg/dl and CRP > 1 mg/L were reported to be
3.1. Whereas, event rates for LDL > 70 mg/dL
and CRP < 1 mg/L were 2.3. When LDL < 70
mg/dL and CRP < 1 mg/L, event rates were the
lowest reported in the study.8
In a 502 patient substudy of the Reversal of
Atherosclerosis with Aggressive Lipid Lowering
(REVERSAL) study7, the extent of both LDL
cholesterol lowering and CRP lowering using the
same statins and doses as in PROVE IT – TIMI 22
were associated with reduced progression of
atheroma volume. Intensive atorvastatin therapy
(80 mg per day) reduced the atheroma progression
rate more than did moderate pravastatin therapy
(40 mg per day). With reductions in LDL
cholesterol and CRP both greater than their
respective median percent changes, total atheroma
volume showed the greatest reduction (-1.98
As in the study by Ridker et al,8
mm3).
correlation between reductions in LDL cholesterol
and reductions in CRP were weak (r = 0.13, P =
0.005). These data indicate that statin reductions
in CRP are independent from statin reductions in
LDL cholesterol. These authors conclude that
their findings suggest that the level of CRP may
be an important therapeutic target. They do not
believe that their data is sufficient to recommend
routine measurements of CRP alone for statin
therapy modification.
The substudy data of the PROVE IT – TIMI 22
trial supports the aggressive use of statins to
achieve target levels of both LDL cholesterol and
CRP for reduction of coronary events in post
acute coronary syndrome patients [Evidence level
A; high-quality RCT].8
Guidelines currently do not recommend
routine use of CRP as a screening test for the
general population. Rather, it is recommended for
detecting enhanced absolute risk in those where
multiple risk factor scoring projects a ten year
coronary heart disease risk in the range of 10% to
20%.9 The American Heart Association (AHA) in
their 2004 Scientific Statement on Preventing
Cancer, Cardiovascular Disease, and Diabetes
identify hs-CRP as an additional factor that may
help in the prognostification of risk.10
More. . .
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Further studies will be needed to answer the
question whether CRP alone will be useful for
initiation and modulation of statin therapy.
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.

Levels of Evidence
In accordance with the trend towards Evidence-Based
Medicine, we are citing the LEVEL OF EVIDENCE
for the statements we publish.
Level
A

B

C
D

Definition
High-quality randomized controlled trial (RCT)
High-quality meta-analysis (quantitative
systematic review)
Nonrandomized clinical trial
Nonquantitative systematic review
Lower quality RCT
Clinical cohort study
Case-control study
Historical control
Epidemiologic study
Consensus
Expert opinion
Anecdotal evidence
In vitro or animal study

Adapted from Siwek J, et al. How to write an evidence-based
clinical review article. Am Fam Physician 2002;65:251-8.
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